info@casimirjones.com
608.662.1277

Lisa L. Mueller, J.D., B.S.

Lisa L. Mueller, J.D., B.S.

Contacts

llmueller@casimirjones.com

For over twenty-five years, Lisa has provided strategic counsel on complex patent issues to clients in the pharmaceutical, biopharmaceutical, biotechnology and chemistry sectors. She brings an in-depth knowledge and extensive experience to her work advising clients on the global patent protection, freedom to operate and validity of blockbuster drugs they aim to produce and distribute.
With a background in chemistry and biology, Lisa provides advice on the full spectrum of global intellectual property portfolio management including patent prosecution, opposition and other post-grant proceedings, and diverse regulatory matters in the following areas:

• Small molecules and biologics

• Drug delivery and drug preparation methods

• Diagnostics and personalized medicine

• Physical and materials sciences

• Food science and nutrition

• Renewable/green chemistry

• Polymer chemistry

• Agricultural, ornamental, vegetable and tree breeding and development (including plant patents and plant variety protection)

Since 2001, Lisa has worked closely with in-house legal departments of global pharmaceutical firms regarding their patent development and enforcement strategies. In this partnership, she provides training to new in-house counsel and meets with scientists and other business development to anticipate and resolve a wide array of problems including navigation of U.S. Food and Drug Administration approval.

A thought leader on pharmaceutical and biopharmaceutical patent law, Lisa speaks frequently to legal and industry groups, and publishes widely. She was the author of an award-winning blog, BRIC Wall, which provides unique insights on patent law developments in the life sciences industry in Brazil, Russia, India and China. Lisa is currently the author of the blog, BRICS & Beyond (https://bricsandbeyond.blog/) which provides unique insights on patent law developments in the life sciences industry not only in Brazil, Russia, India and China but in other countries outside of the United States.

Professional Experience
Shareholder, Casimir Jones S.C., 2018-present
Partner, Michael Best & Friedrich LLP, 2011-2018
Partner, Polsinelli Shughart, 2009-2011
Partner, Dykema Gossett PPC, 2007-2009
Partner, Wood Phillips, 2002-2006
Education
Valparaiso University School of Law, J.D. (magna cum laude,), 1992
Valparaiso University, Chemistry and Biology, B.S., 1985
Admitted
State Bar of Illinois
United States Patent and Trademark Office
U.S. District Court, N.D. of Illinois
Publications and Speaking Engagements
BRICS & BEYOND BLOG

April 25, 2018
Brazilian Mailbox Patents: Big Loss for Alexion

BRICS & BEYOND BLOG

April 19, 2018
Patent Term Extension is Becoming a Reality in China

BRICS & BEYOND BLOG

April 18, 2018
Protecting Life Science Inventions in the Arabian Gulf States – Part 1: Saudi Arabia

BRIC WALL BLOG

February 12, 2018
Working Statements in India: Are You Compliant? – Update

BRIC WALL BLOG

January 21, 2018
Working Statements in India: Are you Compliant?

BRIC WALL BLOG

January 8, 2018
Hitting the Ground Running: The Brazilian Patent Office Publishes New Guidelines Relating to the Examination of Chemical Inventions

BRIC WALL BLOG

December 22, 2017
Draft Intellectual Property Policy of the Republic of South Africa – Phased Implementation – Phase 2 – Part IV

BRIC WALL BLOG

December 08, 2017
Draft Intellectual Property Policy of the Republic of South Africa – Phased Implementation – IP and Public Health – Part III

BRIC WALL BLOG

December 04, 2017
Draft Intellectual Property Policy of the Republic of South Africa – Strategies and Key Reforms – Part II

BRIC WALL BLOG

November 30, 2017
Mexico Faces Renewed Pressure to Implement the 1991 Act of the UPOV Convention

BRIC WALL BLOG

November 28, 2017
Healthcare Reform in the Ukraine and Investment Opportunities for the Private Sector

BRIC WALL BLOG

November 22, 2017
Draft Intellectual Property Policy of the Republic of South Africa – Introduction and Goals

BRIC WALL BLOG

November 22, 2017
The Patent Prosecution Highway (PPH) Pilot Program and the Brazilian PTO – Recent Updates

WEBINAR:

November 09, 2017
Global Patent Strategies for Protecting Plants & Agricultural Products

WEBINAR:

November 01, 2017
Drug Repurposing

BRIC WALL BLOG

November 01, 2017
Understanding Brazil’s Service Guideline #37 for the Examination of Patent Applications Claiming Pharmaceutical Products and Processes

BRIC WALL BLOG

October 25, 2017
Good News in China – Faster Approval for Innovative New Drugs Is on the Way

BRIC WALL BLOG

September 29, 2017
Understanding Bolar and Bolar-Like Exceptions in the U.S. and Abroad – Part 3- Mexico

BRIC WALL BLOG

September 01, 2017
After Years of Waiting, Your or Your Competitor’s Patent Application May Quickly Issue in Brazil. Are You Ready?

BRIC WALL BLOG

August 22, 2017
Understanding Bolar and Bolar-Like Exceptions in the U.S. and Abroad – Part 2 – Canada

BRIC WALL BLOG

July 20, 2017
Understanding Bolar and Bolar-Like Exceptions in the U.S. and Abroad – Part 1

BRIC WALL BLOG

June 26, 2017
Essential Diagnostics Lists to be Developed by WHO

EVENT
ACI Biosimilars Conference, NY, NY

June 14, 2017
Biosimilars around the World: Examining Challenges and Strategies for Creating an International
Biosimilar Portfolio

BRIC WALL BLOG

June 02, 2017
Amendments to the Grace Period in Taiwan for Novelty and Inventive Step

Webinar

May 03, 2017
Subject Matter Eligibility: Avoiding § 101 Issues in Protecting Life Science Inventions & The State of Software Patents Three Years After Alice

BRIC WALL BLOG

April 25, 2017
New guidelines in Brazil give more power to ANVISA in the examination of pharmaceutical patent applications

BRIC WALL BLOG

April 10, 2017
Brazil: Courts confirm preliminary injunction based on pending patent applications

Webinar

February 23, 2017
An Overview of the 21st Century Cures Act

BRIC WALL BLOG

February 09, 2017
Changes to the IP Landscape in Turkey-Industrial Designs

BRIC WALL BLOG

February 02, 2017
Changes to the IP Landscape in Turkey – Patents and Utility Models

BRIC WALL BLOG

January 16, 2017
Two Important Decisions Addressing ANVISA’s Prior Approval of Pharmaceutical Patents in Brazil

BRIC WALL BLOG

January 06, 2017
Delhi High Court Strikes Down Section 24(5) of the Plant Varieties Act as Unconstitutional

BRIC WALL BLOG

December 26, 2016
Property Rights Protection Guideline Released in China

BRIC WALL BLOG

November 29, 2016
Update on Patentability of Diagnostic Claims: Canada (Part 3 of an 8-part Series)

Webinar

November 15, 2016
Patent Prosecution and Enforcement in Turkey, Saudi Arabia, South Africa, Algeria, and Egypt

BRIC WALL BLOG

November 06, 2016
New Requirements in Brazil for Plant Variety Protection Applications in View of Brazil’s Biodiversity Law

BRIC WALL BLOG

October 20, 2016
A Review of Compulsory Licenses in Colombia

BRIC WALL BLOG

October 03, 2016
Ukraine’s Competition Authority Issues a Major Decision on Drug Pricing Practices

PUBLICATION

September 26, 2016
The Effect of FTC Challenges to Pay-For-Delay Agreements: Brand-Name and Generic Companies
Abandon Large Cash Payments and Other Forms of Reverse Payments (American Pharmaceutical Review: https://www.americanpharmaceuticalreview.com/Featured-Articles/190995-The-Effect-of-FTC-Challenges-to-Pay-For-Delay-Agreements-Brand-Name-and-Generic-Companies-Abandon-Large-Cash-Payments-and-Other-Forms-of-Reverse-Payments/)

BRIC WALL BLOG

September 23, 2016
Amendments to Indonesian Patent Law Come into Effect

BRIC WALL BLOG

September 23, 2016
Accelerated Examination of Patent Applications in Argentina

BRIC WALL BLOG

August 29, 2016
Amendments to Indonesian Patent Law Come into Effect

BRIC WALL BLOG

August 19, 2016
Updates to the Brazilian Food and Drug Administration OTC Drug Guidelines

BRIC WALL BLOG

August 05, 2016
Update on Patentability of Diagnostic Claims: Brazil (Part 2 of an 8-part Series)

BRIC WALL BLOG

July 20, 2016
Update on Patentability of Diagnostic Claims: Australia (Part 1 of an 8-part Series)

WEBINAR

July 12, 2016
Patent Prosecution and Enforcement in Thailand, Indonesia, Vietnam, Malaysia and Singapore

BRIC WALL BLOG

June 30, 2016
An Overview of the USTR’s 2016 Special 301 Report on the State of IPR in Argentina

BRIC WALL BLOG

June 27, 2016
An Overview of the USTR’s 2016 Special 301 Report on the State of IPR in Thailand

BRIC WALL BLOG

June 15, 2016
An Overview of the USTR’s 2016 Special 301 Report on the State of IPR in Venezuela

BRIC WALL BLOG

June 13, 2016
India’s Stringent and Shifting Policy on Genetically Modified Cotton Seeds

BRIC WALL BLOG

June 03, 2016
An Overview of the USTR’s 2016 Special 301 Report on the State of IPR in Chile

BRIC WALL BLOG

June 02, 2016
An Overview of the USTR’s 2016 Special 301 Report on the State of IPR in Brazil

BRIC WALL BLOG

May 25, 2016
An Overview of the USTR’s 2016 Special 301 Report on the State of IPR in Algeria and Kuwait

BRIC WALL BLOG

May 23, 2016
An Overview of the USTR’s 2016 Special 301 Report on the State of IPR in China

BRIC WALL BLOG

May 16, 2016
The much awaited Indian National IPR Policy has arrived!

BRIC WALL BLOG

May 16, 2016
IPO’s patent to Gilead’s Sovaldi challenged at Delhi High Court

BRIC WALL BLOG

May 13, 2016
An Overview of the USTR’s 2016 Special 301 Report on the State of IPR in India

Webinar

May 10, 2016
Patent Prosecution and Enforcement in Mexico, Colombia and Chile

BRIC WALL BLOG

May 06, 2016
An Overview of the USTR’s 2016 Special 301 Report on the State of IPR in Russia

Webinar

May 04, 2016
Foreign Filing Restrictions and Licenses

BRIC WALL BLOG

May 02, 2016
An Overview of the USTR’s 2016 Special 301 Report

BRIC WALL BLOG

April 21, 2016
India Patent Office Decision Denying Cipla’s Patent Application for an Anti-Retroviral Combination

BRIC WALL BLOG

March 29, 2016
Expediting Patent Prosecution in Brazil

WEBINAR

March 15, 2016
Patent Prosecution and Enforcement in Brazil, Russia, India and China

BRIC WALL BLOG

March 09, 2016
Roche v. Biocad – Patent litigation likely to shape Russia’s IP landscape

BRIC WALL BLOG

March 04, 2016
Notification Date of Marketing Approval to be used in calculating PTE duration in Israel

BRIC WALL BLOG

February 25, 2016
The Turkish Intellectual Property Court Rules on the Patentability of Genes and Other Nucleic Acid Sequences

BRIC WALL BLOG

February 16, 2016
Brazilian Patent Office and the Patent Prosecution Highway Program

BRIC WALL BLOG

February 08, 2016
Foreign Filing Restrictions and Licenses in Russia – Part 4

BRIC WALL BLOG

January 29, 2016
Foreign Filing Restrictions and Licenses in India – Part 3

BRIC WALL BLOG

January 19, 2016
Foreign Filing Restrictions and Licenses in China – Part 2

BRIC WALL BLOG

January 12, 2016
Foreign Filing Restrictions and Licenses in the U.S. – Part 1

BRIC WALL BLOG

January 08, 2016
Biologics and Biosimilars Bits and Bytes – January 8, 2016

BRIC WALL BLOG

December 30, 2015
Current State of Data Protection and Exclusivity in Russia

BRIC WALL BLOG

December 14, 2015
Merck’s Ezetrol and Patent Term Extension in Israel

BRIC WALL BLOG

December 10, 2015
Biologics and Biosimilars Bits and Bytes – December 10, 2015

BRIC WALL BLOG

November 30, 2015
Biologics and Biosimilars Bits and Bytes – November 30, 2015

BRIC WALL BLOG

November 22, 2015
TPP and the Continuing Controversy Over the Exclusivity Period for Biologics

BRIC WALL BLOG

November 13, 2015
Brazilian Patent and Trademark Office Publishes New Rule on the Prioritization Examination of Patent
Applications

BRIC WALL BLOG

November 05, 2015
A Review of the Patent Related Provisions of the TPP – Patent Revocation, Publication and Delays

BRIC WALL BLOG

October 28, 2015
Brazil: Federal District Court in Rio de Janeiro Declares AstraZeneca’s Patent Covering Fosladex Invalid

BRIC WALL BLOG

October 19, 2015
It’s Status Quo for Now: Federal Circuit Denies Petition for Rehearing En Banc in Amgen v. Sandoz

BRIC WALL BLOG

October 14, 2015
A Review of the Patent Related Provisions of the TPP – Patentable Subject Matter and Grace Periods

BRIC WALL BLOG

October 05, 2015
Jordan FDA Issues a Guideline for the Registration of Biosimilars

BRIC WALL BLOG

September 25, 2015
Amgen is at it Again – Sues Hospira For Not Wanting to Dance Over its Biosimilar

BRIC WALL BLOG

September 18, 2015
Indian Patent Office Rejects Pfizer’s Patent for Tofacitinib – Again!

BRIC WALL BLOG

September 10, 2015
Divisional Applications and the Patent Prosecution Highway Program between U.S. and Mexico

BRIC WALL BLOG

September 02, 2015
Update in Amgen v. Sandoz

BRIC WALL BLOG

August 12, 2015
New Guidelines for the Examination of Polymorph and Salt Patents Issued by the Israeli Patent and Trademark Office

BRIC WALL BLOG

August 03, 2015
Can the Minimum Period of 5 years Established by NAFTA for Regulatory Data Exclusivity be Extended in Mexico for Biological Medical Products?

BRIC WALL BLOG

July 29, 2015
A New Beginning? The Brazilian Patent and Trademark Office has a New President.

BRIC WALL BLOG

July 23, 2015
The Riddle Wrapped in a Mystery Inside an Enigma – The Federal Circuit Decides Amgen v. Sandoz – Is Anyone Happy?

BRIC WALL BLOG

July 14, 2015
New Patent Examination Guidance in Canada for Evaluating Medical Diagnostic Methods: Will Canada’s Application Be More Flexible than the U.S.?

BRIC WALL BLOG

July 07, 2015
Brazil: Strategies and Trends on Intellectual Property Technology Law and Litigation

BRIC WALL BLOG

June 30, 2015
AstraZeneca’s Crestor® Patent is Invalidated by the Brazilian Federal Courts

BRIC WALL BLOG

June 26, 2015
13th Federal District Court of Rio de Janeiro Holds that ANVISA Can Examine Patentability Requirements of Patent Applications Claiming Pharmaceutical Inventions

BRIC WALL BLOG

June 14, 2015
Ariosa Diagnostics, Inc. v. Sequenom, Inc. – Another Diagnostic Patent Meets its End

BRIC WALL BLOG

June 07, 2015
Federal Circuit Hears Oral Arguments in Litigation Involving the First U.S. Biosimilar Product

BRIC WALL BLOG

June 06, 2015
Brazil’s New Biodiversity Law

BRIC WALL BLOG

May 20, 2015

Strategies for Successfully Mastering the Different Challenges of the IP Systems in the BRIC Countries and U.S. in the Pharmaceutical and Life Sciences Sectors

BRIC WALL BLOG

May 11, 2015
Third Party Observations in China – Part 7 of an 8 Part Series

BRIC WALL BLOG

April 27, 2015
Approval of the First Biosimilar Monoclonal Antibody in Brazil

BRIC WALL BLOG

April 27, 2015
Pre-Grant Submissions and Post-Grant Review Proceedings in Brazil – Part 6 of an 8 Part Series

BRIC WALL BLOG

April 19, 2015
Third Party Observations in Europe – Part 5 of an 8 Part Series

BRIC WALL BLOG

April 09, 2015
Third Party Submissions in the U.S. – Part 4 of an 8 Part Series

BRIC WALL BLOG

April 02, 2015
Pre- and Post-Grant Oppositions in India – Part 3 of an 8 Part Series

BRIC WALL BLOG

March 23, 2015
Third Party Submissions in Russia – Part 2 of an 8 Part Series

BRIC WALL BLOG

March 15, 2015
Brazil mailbox litigation update: First case to be heard by the Federal Court of Appeals on March 24, 2015

BRIC WALL BLOG

March 08, 2015
U.S. FDA Approves the First Biosimilar Product

BRIC WALL BLOG

March 06, 2015
Post-Grant Oppositions in Japan – Part 1 of an 8 Part Series

BRIC WALL BLOG

March 06, 2015
Post-Grant Review Proceedings, Oppositions and Third-Party Observations in the U.S., BRIC and other Non-BRIC Countries: An Introduction

BRIC WALL BLOG

February 27, 2015
Taking Advantage of Brazil’s Green Patent Pilot Program

BRIC WALL BLOG

February 15, 2015
Revised Seed Law Expected to Come into Effect Soon in China

BRIC WALL BLOG

February 15, 2015
The Thorny Problem of Patentable Eligible Subject Matter: Part 8 of a 10-Part Series: Australia – A Further Update

BRIC WALL BLOG

February 05, 2015
Is compulsory licensing of generic medicines coming to the Russian Federation?

BRIC WALL BLOG

January 29, 2015
Brazil mailbox litigation update: Good news to start the year for the pharmaceutical industry

BRIC WALL BLOG

January 22, 2015
The Copaxone Story in the U.S. and India: U.S. Supreme Court Decision

BRIC WALL BLOG

January 15, 2015
5 Lessons From FDA’s First Biosimilar Review

BRIC WALL BLOG

January 12, 2015
Inching Closer to the First Biosimilar Approval in the U.S.

BRIC WALL BLOG

January 04, 2015
Be Mindful of Your Claims in Divisional Applications and Patents in South Africa

BRIC WALL BLOG

December 21, 2014
A new list of strategic products creates opportunities for companies in Brazil

BRIC WALL BLOG

December 11, 2014
2014 Year in Review of U.S. Biosimilar Activity

BRIC WALL BLOG

December 07, 2014
The Breadth of India’s “Bolar Exemption”

BRIC WALL BLOG

November 27, 2014
Brazil: An Update of the Most Relevant Events for Pharmaceutical Companies in 2014: Part 3 of a 5-Part Series

BRIC WALL BLOG

November 19, 2014
A Report from the “Biosimilars and Biotech: MENA Conference” in Istanbul, Turkey: Part 1

BRIC WALL BLOG

November 17, 2014
Biosimilars and Biotech: MENA Conference – Istanbul, Turkey – November 18-19th

WEBINAR

November 12, 2014
Navigating the Small Molecule and Formulation Obviousness Highway in View of Recent Federal Circuit Decisions

BRIC WALL BLOG

November 06, 2014
Brazil: An Update of the Most Relevant Events for Pharmaceutical Companies in 2014: Part 2 of a 5-Part Series

BRIC WALL BLOG

November 06, 2014
The Brazilian Patent Office places the fight against the patent application backlog as its top priority

BRIC WALL BLOG

October 27, 2014
A Review of the Status of Biosimilars in the U.S.

BRIC WALL BLOG

October 22, 2014
First Mailbox Appeal to be decided by the Federal Court of Appeals in Brazil: An Update

BRIC WALL BLOG

October 14, 2014
First Mailbox Appeal to be decided by the Federal Court of Appeals in Brazil

BRIC WALL BLOG

October 06, 2014
Patent Term Adjustment: Not available solely in the U.S.

BRIC WALL BLOG

September 22, 2014
Brazil: An Update of the Most Relevant Events for Pharmaceutical Companies in 2014: Part 1 of a 5-Part Series

BRIC WALL BLOG

September 16, 2014
The Thorny Problem of Patentable Eligible Subject Matter: Part 10 of a 10-Part Series: Japan

BRIC WALL BLOG

September 11, 2014a
The Thorny Problem of Patentable Eligible Subject Matter: Part 9 of a 10-Part Series: South Africa

BRIC WALL BLOG

September 05, 2014
The Thorny Problem of Patentable Eligible Subject Matter: Part 8 of a 10-Part Series: Australia – Update

BRIC WALL BLOG

August 28, 2014
The Thorny Problem of Patentable Eligible Subject Matter: Part 8 of a 10-Part Series: Australia

BRIC WALL BLOG

August 18, 2014
The Thorny Problem of Patentable Eligible Subject Matter: Part 7 of a 10-Part Series: China

BRIC WALL BLOG

August 05, 2014
The Thorny Problem of Patentable Eligible Subject Matter: Part 6 of a 10-Part Series: Europe

BRIC WALL BLOG

July 30, 2014
The Race is on! Anxiously Waiting for the First U.S. Biosimilar to Cross the Finish Line

BRIC WALL BLOG

July 24, 2014
The Thorny Problem of Patentable Eligible Subject Matter: Part 5 of a 10-Part Series: Brazil

BRIC WALL BLOG

July 16, 2014
The Thorny Problem of Patentable Eligible Subject Matter: Part 4 of a 10-Part Series: Russia

BRIC WALL BLOG

July 10, 2014
The Thorny Problem of Patentable Eligible Subject Matter: Part 3 of a 10-Part Series: India

BRIC WALL BLOG

July 08, 2014
Patent Troll Update: Brazil

BRIC WALL BLOG

June 25, 2014
Is an Abbreviated Pathway for Biosimilars Coming Soon to China?

BRIC WALL BLOG

June 20, 2014
Availability of Biosimilar Pathways and Data/Marketing Exclusivity Globally: Update

BRIC WALL BLOG

June 13, 2014
Cloning: It’s not what you think – Changes to ANVISA’s “clone” procedure

BRIC WALL BLOG

June 04, 2014
Availability of Biosimilar Pathways and Data/Marketing Exclusivity Globally

BRIC WALL BLOG

May 29, 2014
An Overview of Biosimilars in the Russian Federation

BRIC WALL BLOG

May 21, 2014
An Overview of Biosimilars and the Biosimilar Pathway in India

BRIC WALL BLOG

May 11, 2014
The Thorny Problem of Patentable Eligible Subject Matter: Update to Part 1 of the 10-Part Series: U.S.

BRIC WALL BLOG

May 09, 2014
The Thorny Problem of Patentable Eligible Subject Matter: Part 2 of a 10-Part Series: Canada

BRIC WALL BLOG

April 30, 2014
The Thorny Problem of Patentable Eligible Subject Matter: Part 1 of a 10-Part Series: U.S

BRIC WALL BLOG

April 23, 2014
The Copaxone Story in the U.S. and India: To Stay or Not to Stay is the Question

BRIC WALL BLOG

April 14, 2014
The Thorny Problem of Patentable Eligible Subject Matter: An Introduction

BRIC WALL BLOG

April 09, 2014
The Copaxone Story in the U.S. and India: A Further Update

BRIC WALL BLOG

April 04, 2014
The Copaxone Story in the U.S. and India: An Update

BRIC WALL BLOG

April 01, 2014
Divisional Practice in the BRICs and Other Countries – Part 9 of a 9-Part Series: A Comprehensive
Summary

BRIC WALL BLOG

March 26, 2014
Protecting and Enforcing Trade Secrets in China

BRIC WALL BLOG

March 19, 2014
Divisional Practice in the BRICs and Other Countries – Part 8 of a 9-Part Series: Europe

BRIC WALL BLOG

March 14, 2014
BRIC-a-BRAC: March 14, 2014

BRIC WALL BLOG

March 12, 2014
Understanding Obviousness in Pakistan

BRIC WALL BLOG

March 05, 2014
The Copaxone Story in the U.S. and India

BRIC WALL BLOG

February 26, 2014
Clarity regarding the use of Post-Filing Data in China?

BRIC WALL BLOG

February 24, 2014
Patent Trolls: A View from Europe

BRIC WALL BLOG

February 19, 2014
Patent Troll Update: Japan

BRIC WALL BLOG

February 16, 2014
Patent Trolls: A Global Perspective

BRIC WALL BLOG

February 11, 2014
Pay Your Annuities in Brazil!

BRIC WALL BLOG

February 06, 2014
Divisional Practice in the BRICs and other Countries – Part 7 of a 9-Part Series: Canada

BRIC WALL BLOG

February 05, 2014
BRIC-a-BRAC: February 5, 2014

BRIC WALL BLOG

January 31, 2014
BRIC-a-BRAC: January 31, 2014

BRIC WALL BLOG

January 29, 2014
Divisional Practice in the BRICs and other Countries – Part 6 of a 9-Part Series: China

BRIC WALL BLOG

January 24, 2014

BRIC-a-BRAC: January 24, 2014

BRIC WALL BLOG

January 21, 2014
Regulatory Pathway for Biosimilar Products in Nigeria

BRIC WALL BLOG

January 20, 2014
BRIC-a-BRAC

BRIC WALL BLOG

January 17, 2014
BRIC-a-BRAC

BRIC WALL BLOG

January 15, 2014
Time Period and Burden of Proof Requirements when Requesting Revocation of a Patent in Kenya

BRIC WALL BLOG

January 10, 2014
BRIC-a-BRAC

BRIC WALL BLOG

January 07, 2014
Has Inequitable Conduct Come to India?

BRIC WALL BLOG

January 06, 2014
BRIC-a-BRAC

BRIC WALL BLOG

January 01, 2014
Helping Clients Understand Biosimilar Product Regulations and the Biosimilar Litigation Process

BRIC WALL BLOG

December 24, 2013
Brazil’s Ministry of Health Issues New List of “Strategic” Drugs

BRIC WALL BLOG

December 18, 2013
Divisional Practice in the BRICs and other Countries – Part 5 of a 9-Part Series: Russia

BRIC WALL BLOG

December 10, 2013
Divisional Practice in the BRICs and other Countries – Part 4 of a 9-Part Series

BRIC WALL BLOG

December 02, 2013
Divisional Practice in the BRICs and other Countries – Part 3

BRIC WALL BLOG

November 21, 2013
Divisional Practice in the BRICs and other Countries – Part 2

BRIC WALL BLOG

November 13, 2013
Divisional Practice in the BRICs and other Countries – Part 1

BRIC WALL BLOG

November 09, 2013
Should ANVISA be Permitted to Reject Pharmaceutical Patent Applications in Brazil?

BRIC WALL BLOG

November 07, 2013
Is the Patent Term “Guarantee” in Brazil Unconstitutional?

BRIC WALL BLOG

November 03, 2013

Request for Public Comments by ANVISA on the Interchangeability of Branded Generic Drugs with Reference Drugs in Brazil

BRIC WALL BLOG

October 29, 2013
Nigeria Patent Protection: The Basics – Part 2 of a 2-Part Series

BRIC WALL BLOG

October 16, 2013
Nigeria Patent Protection: The Basics – Part 1 of a 2-Part Series

BRIC WALL BLOG

October 14, 2013
Recent Brazilian Jurisprudence Concerning the Scope of ANVISA’s Prior Consent

BRIC WALL BLOG

October 01, 2013
The Problem of Mailbox Patents and Patent Term in Brazil

BRIC WALL BLOG

September 30, 2013
Availability of Biosimilar Pathways and Data Exclusivity in Asian, Latin American and Eastern European Countries

BRIC WALL BLOG

September 18, 2013
Patentees Can Continue Patent Infringement Lawsuits in Russia Even if a Patent is Found to Be Partially Invalid

BRIC WALL BLOG

September 12, 2013
Understanding Biologics and Biosimilars in Turkey

BRIC WALL BLOG

September 04, 2013
Understanding Biologics and Biosimilars in Brazil

BRIC WALL BLOG

August 26, 2013
Section 8 of the Indian Patents Act and a Comparison with the Disclosure Requirements in Canada, Israel and the U.S.

BRIC WALL BLOG

August 08, 2013
Recent Decisions involving Section 3(d) of the Indian Patents Act

BRIC WALL BLOG

August 08, 2013
The Elusive Patent Expiration Date

BRIC WALL BLOG

July 23, 2013
Patent Term Extension in Russia

BRIC WALL BLOG

July 19, 2013
Supplementary Protection Certificates and Pediatric Extensions in Croatia

BRIC WALL BLOG

July 10, 2013
New Russian Intellectual Property Court is Open

BRIC WALL BLOG
July 05, 2013
International Survey of the Patentability of Genes, Proteins and Other Genetic Materials

BRIC WALL BLOG

June 25, 2013
Recent Brazilian Federal Court Decision Involving Genetic Heritage and Traditional Knowledge

BRIC WALL BLOG

June 19, 2013
Proposed Increase in Official Fees in Connection with Patent Filings in India

BRIC WALL BLOG

June 07, 2013
Section 3(d) of the Indian Patents Act – Part I

BRIC WALL BLOG

May 30, 2013
Examination of Pharmaceutical Patent Applications by ANVISA In Brazil

BRIC WALL BLOG

May 23, 2013
Understanding Chinese Inventor Reward and Remuneration